Xenetic Biosciences Stock Buy Hold or Sell Recommendation
| XBIO Stock | USD 4.11 0.10 2.49% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Xenetic Biosciences is 'Strong Sell'. The recommendation algorithm takes into account all of Xenetic Biosciences' available fundamental, technical, and predictive indicators you will find on this site.
Check out Xenetic Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide. In addition, we conduct extensive research on individual companies such as Xenetic and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Xenetic |
Execute Xenetic Biosciences Buy or Sell Advice
The Xenetic recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Xenetic Biosciences. Macroaxis does not own or have any residual interests in Xenetic Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Xenetic Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Xenetic Biosciences Trading Alerts and Improvement Suggestions
| Xenetic Biosciences had very high historical volatility over the last 90 days | |
| Xenetic Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.54 M. Net Loss for the year was (4.13 M) with profit before overhead, payroll, taxes, and interest of 1.16 M. | |
| Xenetic Biosciences currently holds about 14.93 M in cash with (4.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. | |
| Xenetic Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 19.0% of the company outstanding shares are owned by insiders | |
| Latest headline from finance.yahoo.com: Xenetic Biosciences, Inc. Releases Virtual Investor What This Means Segment |
Xenetic Biosciences current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Xenetic analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Xenetic analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Xenetic Biosciences Returns Distribution Density
The distribution of Xenetic Biosciences' historical returns is an attempt to chart the uncertainty of Xenetic Biosciences' future price movements. The chart of the probability distribution of Xenetic Biosciences daily returns describes the distribution of returns around its average expected value. We use Xenetic Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Xenetic Biosciences returns is essential to provide solid investment advice for Xenetic Biosciences.
| Mean Return | 0.04 | Value At Risk | -7.27 | Potential Upside | 7.65 | Standard Deviation | 5.00 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Xenetic Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Xenetic Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Xenetic Biosciences, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Xenetic Biosciences back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Sachetta Llc | 2024-09-30 | 17.4 K | Renaissance Technologies Corp | 2024-09-30 | 15.8 K | Geode Capital Management, Llc | 2024-09-30 | 11.9 K | Jtc Employer Solutions Trustee Ltd | 2024-09-30 | 2.7 K | Ubs Group Ag | 2024-06-30 | 182 | Bank Of America Corp | 2024-06-30 | 11.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.0 | Harwood Advisory Group, Llc | 2024-09-30 | 2.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 | Steward Partners Investment Advisory, Llc | 2024-06-30 | 0.0 |
Xenetic Biosciences Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 9.7M | 1.2M | 6.7M | (5.1M) | (4.1M) | (3.9M) | |
| Free Cash Flow | (6.4M) | (4.3M) | (4.7M) | (5.1M) | (4.1M) | (4.3M) | |
| Depreciation | 15.8K | 27.5K | 28.8K | 35.5K | 27.0K | 0.0 | |
| Other Non Cash Items | 3.0M | 9.1M | 24.3K | 1.8M | 546.7K | 519.3K | |
| Net Income | (12.8M) | (10.9M) | (5.6M) | (6.6M) | (4.1M) | (4.3M) | |
| End Period Cash Flow | 10.4M | 11.5M | 18.2M | 13.1M | 9.0M | 8.3M | |
| Change Receivables | 3.3M | (251.8K) | (653.6K) | 325.7K | 374.5K | 393.2K | |
| Change To Netincome | 1.3M | 4.1M | 6.6M | 410.4K | 369.4K | 350.9K |
Xenetic Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Xenetic Biosciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Xenetic Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Xenetic stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.0087 | |
β | Beta against Dow Jones | 0.35 | |
σ | Overall volatility | 5.06 | |
Ir | Information ratio | -0.02 |
Xenetic Biosciences Volatility Alert
Xenetic Biosciences exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Xenetic Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Xenetic Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Xenetic Biosciences Fundamentals Vs Peers
Comparing Xenetic Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Xenetic Biosciences' direct or indirect competition across all of the common fundamentals between Xenetic Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Xenetic Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Xenetic Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Xenetic Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Xenetic Biosciences to competition |
| Fundamentals | Xenetic Biosciences | Peer Average |
| Return On Equity | -0.49 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Profit Margin | (1.86) % | (1.27) % |
| Operating Margin | (1.84) % | (5.51) % |
| Current Valuation | (507.28 K) | 16.62 B |
| Shares Outstanding | 1.54 M | 571.82 M |
| Shares Owned By Insiders | 19.05 % | 10.09 % |
| Shares Owned By Institutions | 2.09 % | 39.21 % |
| Number Of Shares Shorted | 14.83 K | 4.71 M |
| Price To Earning | (1.81) X | 28.72 X |
| Price To Book | 0.90 X | 9.51 X |
| Price To Sales | 2.51 X | 11.42 X |
| Revenue | 2.54 M | 9.43 B |
| Gross Profit | 1.16 M | 27.38 B |
| EBITDA | (4.52 M) | 3.9 B |
| Net Income | (4.13 M) | 570.98 M |
| Cash And Equivalents | 14.93 M | 2.7 B |
| Cash Per Share | 1.04 X | 5.01 X |
| Total Debt | 809.59 K | 5.32 B |
| Current Ratio | 12.02 X | 2.16 X |
| Book Value Per Share | 6.36 X | 1.93 K |
| Cash Flow From Operations | (4.11 M) | 971.22 M |
| Short Ratio | 0.77 X | 4.00 X |
| Earnings Per Share | (2.66) X | 3.12 X |
| Target Price | 40.0 | |
| Number Of Employees | 4 | 18.84 K |
| Beta | 2.26 | -0.15 |
| Market Capitalization | 6.33 M | 19.03 B |
| Total Asset | 10.61 M | 29.47 B |
| Retained Earnings | (193.23 M) | 9.33 B |
| Working Capital | 8.78 M | 1.48 B |
| Current Asset | 1.21 M | 9.34 B |
| Current Liabilities | 4.97 M | 7.9 B |
Note: Acquisition by James Parslow of 20000 shares of Xenetic Biosciences at 3.99 subject to Rule 16b-3 [view details]
Xenetic Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Xenetic . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Xenetic Biosciences Buy or Sell Advice
When is the right time to buy or sell Xenetic Biosciences? Buying financial instruments such as Xenetic Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Xenetic Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run World Allocation Funds Thematic Idea Now
World Allocation Funds
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Xenetic Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.638 | Quarterly Revenue Growth 0.116 | Return On Assets (0.29) | Return On Equity (0.49) |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.